MALMÖ, Sweden, Oct. 31, 2019 /PRNewswire/ — – Positive results from a pooled analysis of Phase 2 trials with imlifidase for desensitization in highly sensitized kidney transplant patients were presented for the first time at the European Society of Organ Transplantation’s (ESOT) Congress…